Interleukin-1 receptor type II - Immunex

Drug Profile

Interleukin-1 receptor type II - Immunex

Alternative Names: IL-1RII - Amgen; Interleukin-1 receptor type 2 - Amgen; Soluble interleukin-1 receptor type II - Amgen

Latest Information Update: 10 Sep 2008

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Immunex
  • Class Antirheumatics
  • Mechanism of Action Interleukin 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Postmenopausal osteoporosis; Rheumatoid arthritis

Most Recent Events

  • 24 Sep 2002 A clinical study has been added to the adverse events and pharmacokinetics sections
  • 24 Jul 2002 Immunex has been acquired by, and merged into, Amgen
  • 31 Dec 2001 Phase-I clinical trials for Rheumatoid arthritis in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top